Skip to content

Medication adherence management in a community pharmacy setting (AdherenciaMED): a cluster randomized controlled trial

The effect of a medication adherence management service in a community pharmacy setting on patient's adherence to medications: a cluster randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000410257
Enrollment
1222
Registered
2018-03-21
Start date
2017-09-29
Completion date
2017-11-24
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Non-adherence to medications has a significant impact on health outcomes, affecting patients, health care professionals and health care system, especially in patients suffering from Asthma, COPD and Hypertension. Brief complex interventions based on change behaviour theories have demonstrated to be effective on improving and maintaining adherence; with the ones involving pharmacist having the most positive impact. This study is a cluster randomized controlled trial targeted at patients using hypertension, COPD and asthma medications. The study will be undertaken in community pharmacies across 6 Spanish provinces. It is estimated that approximately 120 pharmacies and 1230 patients will participate during this 6-months trial. Pharmacies will be randomised to either intervention or control group. Patients in the intervention group will receive a medication adherence management, based on different evidence-based theoretical frameworks for changing patient behaviour. Clinical, humanistic and economic outcomes will be measured to evaluate the impact of the service. This study will provide a model of Professional Pharmacy Service focused on improvement and maintenance of adherence on patients being treated with hypertension, asthma or chronic obstructive pulmonary disease (COPD) medicines compared to usual care, and its effectiveness in enhancing health outcomes.

Interventions

Patient tailored brief complex interventions to improve, reinforce and maintain adherence behaviour and their impact in clinical, economical and humanistic outcomes. The intervention will be delivered by pharmacists, in community pharmacies distributed in 6 provinces in Spain to patients with medications for treating asthma, COPD and hypertension. A total of six monthly face to face interviews will be agreed between the pharmacist and the patient in a consultation hold on a counselling area. Al

Patient tailored brief complex interventions to improve, reinforce and maintain adherence behaviour and their impact in clinical, economical and humanistic outcomes. The intervention will be delivered by pharmacists, in community pharmacies distributed in 6 provinces in Spain to patients with medications for treating asthma, COPD and hypertension. A total of six monthly face to face interviews will be agreed between the pharmacist and the patient in a consultation hold on a counselling area. All the data will be recorded in an electronic data collection form specifically developed for the study. Before patient recruitment, pharmacists allocated to the Intervention group will be trained on the study protocol and service delivery, The training will be provided by the members of the research team, and will involve theoretical and practical (role play) approaches. It will be focused on clinical aspects of the conditions, adherence management, including the application of several frameworks for changing patient behaviour (motivational interviewing, health belief model, necessity and concerns model, information-motivation-strategy model and transtheoretical model). During each interview a review of the patient's current medications will be undertaken. The dispensing dates of each medication will also be recorded, based on the pharmacy refill data. These variables will be used for the further calculation proportion of days covered. All the new medications and clinical conditions will be recorded. The pharmacist then will assess (1) medication adherence (through the Morisky-4 self report questionnaire) and (2) inhaler technique (through a specific inhaler device checklist). This step will only be undertaken in patients with COPD or asthma. Based on these responses the patient will be identified in one of the four categories of non-adherence (intentional, non-intentional, combined, erratic). The concepts of Motivational Interviewing will be applied throughout the whole pharmacist-patient interaction and specific models will be used based on the patient's classification of non-adherence. For all the non-adherent patients, the health belief model, Necessity and Concerns, Information-Motivation-Strategy and Transtheoretical model will be applied. A list of barriers and strategies has been defined based on defined determinants of non-adherence according to the World Health Organization; and also strategies to maintain and reinforce adherence in adherent patients. Strategies will cover educational (e.g. written or oral information), social (e.g. family support), healthcare communication (e.g. regimen simplification or change) or medication aids (e.g. dose taking aids, phone messages, alarms) amongst others. The project will be monitored by Practice Change Facilitators (PCF), who will ensure the quality of the service delivery and will support the participant pharmacists through monthly visits.

Sponsors

Consejo General de Colegios Oficiales de Farmaceuticos
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Educational / counselling / training
Masking
Blinded (masking used) (Subject)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1) Age>18 years, 2) Having signed informed consent; 3) Able to complete questionnairesEuroQol-5D, Morisky 4 items, ACQ (Asthma Control Questionnaire), COPD assessment test; 4) Being prescribed either a blood pressure medication (medicines included in groups CO2, CO3, C07, C08, C09, according to Anatomical Therapeutical Chemical ATC classification system), an asthma medication (medicines included in group R03), or an COPD medication (medicines included in group R03).

Exclusion criteria

1) People who are collecting someone else’s medication, 2) Patients who are pregnant or lactating, 3) Patients who cannot be at the pharmacy on a regular basis, 4) Patients who have previously participated in any education program or study related to the improvement of adherence to medications, 5) Patients who have communication limitations or any other impairment the recruiting pharmacist considers could preclude them from participating on the study.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 15, 2026